Evidence map›Paper›PMID 35309874›Full record

ReviewEuropean journal of radiology open2022

Teaching cancer imaging in the era of precision medicine: Looking at the big picture.

Christopher N Chin, Ty Subhawong, James Grosso, Jeremy R Wortman, Lacey J McIntosh, Ryan Tai, Marta Braschi-Amirfarzan, Patricia Castillo, Francesco Alessandrino

Abstract readReview
In one paragraph

Review in European journal of radiology open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. What's new in cancer and molecular imaging.European journal of radiology open · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Christopher N ChinDepartment of Surgery, Leonard M. Miller School of Medicine, Miami, FL, USA.
Ty SubhawongDepartment of Radiology, Leonard M. Miller School of Medicine, Miami, FL, USA.
James GrossoDepartment of Radiology, Leonard M. Miller School of Medicine, Miami, FL, USA.
Jeremy R WortmanDepartment of Radiology, Lahey Health Medical Center, Beth Israel Lahey Health, Tufts University school of Medicine, Boston, MA, USA.
Lacey J McIntoshDepartment of Radiology, University of Massachusetts Chan Medical School, Memorial Health Care, Worcester, MA, USA.
Ryan TaiDepartment of Radiology, University of Massachusetts Chan Medical School, Memorial Health Care, Worcester, MA, USA.
Marta Braschi-AmirfarzanDepartment of Radiology, Lahey Health Medical Center, Beth Israel Lahey Health, Tufts University school of Medicine, Boston, MA, USA.
Patricia CastilloDepartment of Radiology, Leonard M. Miller School of Medicine, Miami, FL, USA.
Francesco AlessandrinoDepartment of Radiology, Leonard M. Miller School of Medicine, Miami, FL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The role of imaging in cancer diagnosis and treatment has evolved at the same rapid pace as cancer management. Over the last twenty years, with the advancement of technology, oncology has become a multidisciplinary field that allows for researchers and clinicians not only to create individualized treatment options for cancer patients, but also to evaluate patients' response to therapy with increasing precision. Familiarity with these concepts is a requisite for current and future radiologists, as cancer imaging studies represent a significant and growing component of any radiology practice, from tertiary cancer centers to community hospitals. In this review we provide the framework to teach cancer imaging in the era of genomic oncology. After reading this article, readers should be able to illustrate the basics cancer genomics, modern cancer genomics, to summarize the types of systemic oncologic therapies available, their patterns of response and their adverse events, to discuss the role of imaging in oncologic clinical trials and the role of tumor response criteria and to display the future directions of oncologic imaging.

Indexed as

Adverse events, clinical trialsCheckpoint inhibitorsMolecular targeted therapiesOncologic imagingTumor response criteria

Identifiers

PMID35309874
PMCPMC8927915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.